EGFR and non-small cell lung carcinoma: In summary, our findings suggest that concomitant EGFR and ERK blockade is a promising strategy to overcome acquired resistance in EGFR-mutated NSCLC regardless of whether the acquired resistance arises from first- or third-generation EGFR TKIs.